midazolam has been researched along with repaglinide in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ | 1 |
| Maren, K; Rojkjaer, L; Skerjanec, A; Wang, J | 1 |
| Cao, Y; Jusko, WJ | 1 |
| Chun, DY; Einolf, HJ; Gu, H; Sangana, R | 1 |
| Gaudette, F; Huguet, J; Michaud, V; Turgeon, J | 1 |
| Bairlein, M; Gerisch, M; Heinig, R; Loewen, S; Nagelschmitz, J | 1 |
| Hoch, M; Hourcade-Potelleret, F; Sengupta, T | 1 |
| Fan, Y; Feng, S; Fu, M; Gu, F; Huang, J; Lin, H; Lu, Z; Luo, L; Shen, K; Wu, B | 1 |
1 review(s) available for midazolam and repaglinide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for midazolam and repaglinide
| Article | Year |
|---|---|
Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.
Topics: Adult; Anesthetics, Intravenous; Aryl Hydrocarbon Hydroxylases; Benzoates; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Deferasirox; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Iron Chelating Agents; Male; Midazolam; Piperidines; Rifampin; Triazoles | 2010 |
Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications.
Topics: Administration, Oral; Adolescent; Adult; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Double-Blind Method; Drug Interactions; Germany; Humans; Isoenzymes; Male; Midazolam; Middle Aged; Mineralocorticoid Receptor Antagonists; Models, Biological; Naphthyridines; Piperidines; Substrate Specificity; Warfarin; Young Adult | 2020 |
Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants.
Topics: Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Niacinamide; Piperidines; Pyrazoles; Warfarin | 2022 |
12 other study(ies) available for midazolam and repaglinide
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin | 2005 |
Applications of minimal physiologically-based pharmacokinetic models.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; beta-Lactams; Biological Availability; Carbamates; Codeine; Humans; Kinetics; Liver; Midazolam; Models, Biological; Piperidines; Regional Blood Flow; Verapamil | 2012 |
Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches.
Topics: Antitubercular Agents; Area Under Curve; Carbamates; Clofazimine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Desipramine; Drug Interactions; Humans; Midazolam; Models, Biological; Piperidines; Tuberculosis, Multidrug-Resistant | 2018 |
Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes.
Topics: Bupropion; Butyrophenones; Carbamates; Chlorzoxazone; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Ethanolamines; Humans; Lauric Acids; Microsomes; Midazolam; Myocardium; Oxazines; Piperidines; Tolbutamide | 2019 |
Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Omeprazole; Warfarin | 2023 |